The Safety and Antiviral Efficacy of Stavudine Extended Release Formulation as Compared to Stavudine Immediate Release Formulation, Each as Part of Potent Antiretroviral Combination Therapy

CompletadoFase 3ClinicalTrials.gov

ID: NCT00005918Tipo: INTERVENTIONALInicio: 1 de jun de 2000Fin estimado: 1 de abr de 2002

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).

Descripción detallada

Patients are randomized to receive blinded stavudine extended release (d4T ER) or immediate release (d4T IR) formulation. Randomization is balanced by screening HIV viral load of less than 30,000 copies/ml or at least 30,000 copies/ml and by site. Patients also receive open-label efavirenz (EFV) and lamivudine (3TC). Efficacy is evaluated over 48 weeks of the dosing period and safety is evaluated over the entire dosing period (56 weeks).

Elegibilidad

Edad mínima: 12 YearsSexo: ALL

Criterios de inclusión

Patients may be eligible for this study if they:
Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18).
Have a viral load of at least 2,000 copies/ml within 21 days of study entry.
Have a CD4 count of at least 100 cells/mm3 within 21 days of study entry.
Agree to use a barrier method of birth control (such as condoms) during the study.
Are available for follow-up for at least 56 weeks.

Criterios de exclusión

Patients will not be eligible for this study if they:
Are pregnant or breast-feeding.
Have taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) for more than 30 days and within 14 days of study entry.
Have a new opportunistic (HIV-related) infection or condition requiring treatment.
Have acute (early) HIV infection.
Have diarrhea (at least 6 loose stools/day for at least 7 days in a row) within 30 days prior to study entry.
Abuse alcohol or drugs.
Have active hepatitis within 30 days prior to study entry.
Have a history of peripheral neuropathy (a condition affecting the nervous system).
Cannot take medications by mouth.
Are allergic to certain antiviral drugs.
Need to take certain medications that should not be taken with EFV.
Have certain other conditions or prior treatments that might affect the study.

Intervenciones

drug

Efavirenz

drug

Lamivudine

drug

Stavudine

Ubicaciones

Arnaldo Casiro MD

Buenos Aires, Argentina

Claudia Rodriguez MD

Buenos Aires, Argentina

Elida Pallone MD

Buenos Aires, Argentina

Fundacion Huesped

Buenos Aires, Argentina

Luis Maria Zieher MD

Buenos Aires, Argentina

Fernando Silva Nieto MD

Prov Bs As, Argentina

CAICI

Rosario Santa Fe, Argentina

Marcelo Beltran

San Isidro, Argentina

Patrocinadores

PrincipalBristol-Myers Squibb

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

The Safety and Antiviral Efficacy of Stavudine Extended R... | EligiMed